Cargando…

Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant disease and is considered the fourth leading cause of death among cancer patients in the United States. Mutations in the BRCA gene, which is a DNA repair gene, increase the risk of PDAC, and among all patients with PDAC, about 8%-10% have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asiri, Mohamed S, Dabaliz, Alhomam, Almutairi, Mahdi, Almahbub, Abdulaziz, Alharbi, Mohammed, Almeman, Sarah, AlShieban, Saeed, Alotaibi, Tareq, Algarni, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492221/ https://www.ncbi.nlm.nih.gov/pubmed/37692681 http://dx.doi.org/10.7759/cureus.43261

Ejemplares similares

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Pathological Features and Clinical Characteristics of Kikuchi-Fujimoto Disease: A Tertiary Hospital Experience in Riyadh, Saudi Arabia
por: AlShieban, Saeed, et al.
Publicado: (2023)

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Complete pathological response of post neoadjuvant chemotherapy in colorectal cancer with liver metastasis: a case report
por: Al Jazzar, Ragad I, et al.
Publicado: (2022)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy
por: Al Shboul, Sofian, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy
por: Alhesa, Ahmad, et al.
Publicado: (2022)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Reducing turnaround time of surgical pathology reports in pathology and laboratory medicine departments
por: Alshieban, Saeed, et al.
Publicado: (2015)

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
por: Turner, Nicholas C, et al.
Publicado: (2012)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

The Efficacy and Response Predictors of Platinum-Based Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
por: Huang, Yuhui, et al.
Publicado: (2020)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
por: Yu, Xiao-Li, et al.
Publicado: (2021)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

A meta‐analysis comparing efficiency of limb‐salvage surgery vs amputation on patients with osteosarcoma treated with neoadjuvant chemotherapy
por: Abdelgawad, Mohamed A, et al.
Publicado: (2022)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Tumor histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive?
por: Hanafy, Ehab, et al.
Publicado: (2018)

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
por: Tsyganov, Matvey M., et al.
Publicado: (2023)

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
por: Mylavarapu, Sanghamitra, et al.
Publicado: (2018)

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
por: Guo, Lei, et al.
Publicado: (2019)

Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
por: Zhang, Kai, et al.
Publicado: (2020)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Natural Killer Cell Lymphoblastic Leukaemia/Lymphoma: Case Report and Review of the Recent Literature
por: Sedick, Qanita, et al.
Publicado: (2017)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
por: Margeli, Mireia, et al.
Publicado: (2010)

Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report
por: Lin, Zhenyu, et al.
Publicado: (2018)

Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Publicado: (2020)

An insidious case of infectious mononucleosis presenting with acute appendicitis diagnosed postoperatively: a case report
por: AlMudaiheem, Faisal A, et al.
Publicado: (2021)

Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy
por: Saleh, Tareq, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response
por: Mohammed, Amrallah A, et al.
Publicado: (2020)

Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
por: Rimar, Kalen J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_10n7v307emgu173tv5fcbkthnq